Evidence map›Paper›PMID 41276548›Full record

ArticleScientific reports2025

Investigating of harmane, harmine, and norharman as inhibitors of MDR1 and MRP1 to overcome chemotherapy resistance in cancer cells.

Neda Abdi, Arezou Banitalebi, Razieh Heidari, Sorur Zahedian, Seyed Abbas Mirzaei, Fatemeh Elahian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Neda Abdi *Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Arezou Banitalebi *Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Razieh HeidariDepartment of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Sorur ZahedianDepartment of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Seyed Abbas MirzaeiDepartment of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Fatemeh ElahianCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran. elahian.a@skums.ac.ir.

Funding

Shahrekord University of Medical Sciences SKUMS-5204Shahrekord University of Medical Sciences SKUMS-5206
6 · The paper itself

Abstract

Multidrug resistance efflux pumps are among the primary contributors to chemotherapy failure. Therefore, the identification of novel inhibitors with greater specificity and efficacy remains a critical objective. Here the effects of harmane, harmine, and norharman were investigated on the activity of P-gp and MRP1 transporters in the EPG85.257RDB and A2780 cell lines. The lipophilicity of these compounds and their potential interactions with the transporters were assessed via molecular docking. Cytotoxicity, changes in the IC

Indexed as

ATP-Binding Cassette, Sub-Family C ProteinsDrug Resistance, NeoplasmHarmineAlkaloidsAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BCarbolinesCell Line, TumorDaunorubicinDrug Resistance, MultipleHumansMolecular Docking SimulationABCB1 protein, humanAlkaloidsAntineoplastic AgentsATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter, Subfamily BCarbolinesDaunorubicinharmanHarminemultidrug resistance-associated protein 1norharmanHarmaneHarmineMDR1MRP1NorharmanP-gpΒ-carboline alkaloids

Identifiers

PMID41276548
PMCPMC12748654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.